Another selective ALK2 inhibitor, INCB000928 that was originally developed to treat anemia as an iron homeostasis modulator, is now being evaluated for the efficacy and tolerability in the treatment of FOP in the phase II clinical trial (NCT05090891) [51, 52] (Table 1). Here, ACVR1 is linked to fibrodysplasia ossificans progressiva.